Predictive Value of Age-Adjusted Charlson Comorbidity Index on Survival Outcomes of Hepatocellular Carcinoma Patients with Comorbidities Undergoing Radiofrequency Ablation
Authors:
- Yuzheng YanYYYuzheng Yan
- Sijie XiaoSXSijie Xiao
- Feng XiaFXFeng Xia
- Huaqiang BiHBHuaqiang Bi
- Chunlin TangCTChunlin Tang
- Kai FengKFKai Feng
- Kuansheng MaKMKuansheng Ma
- Qiang WangQWQiang Wang
Open Access
- 1 April 2026
- journal article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Abstract
This study aimed to explore the predictive value of Age-Adjusted Charlson Comorbidity Index (ACCI) on survival outcomes in patients with hepatocellular carcinoma (HCC) and comorbidities undergoing radiofrequency ablation (RFA). This study is a retrospective, single-center study which included 158 patients with HCC newly diagnosed at our center from January 2015 to December 2021 who had comorbidities prior to RFA treatment. Patients were divided into two groups (≤4 and >4) according to the optimal cutoff value of ACCI determined by X-tile analysis based on overall survival (OS), and comprehensive clinical, laboratory, and tumor characteristic data were collected. The primary endpoints were OS and recurrence-free survival (RFS), analyzed using the Kaplan-Meier method and Cox proportional hazards model. Patients in the high ACCI group (>4) were independently associated with worse OS and RFS compared to those in the low ACCI group (≤4). Multivariate Cox analysis confirmed that ACCI >4 was an independent risk factor for both OS and RFS, with hazard ratios (HR) of 2.07 and 2.05, respectively. In addition to ACCI, other independent predictors for worse OS included tumor max-diameter (HR: 1.69, P < 0.001) and elevated level of preoperative α-fetoprotein (HR: 1.91, P = 0.007), while preoperative albumin (HR: 0.93, P=0.001) was a significant protective factor for OS. For RFS, significant risk factors included tumor max-diameter (HR: 1.79, P < 0.001) and prothrombin time ≥ 13 seconds (HR: 2.38, P = 0.001). ACCI may serve as a useful prognostic predictor for survival outcomes in HCC patients with comorbidities undergoing RFA.Keywords
This publication has 31 references indexed in Scilit:
- Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and LipogenesisHepatology, 2021
- Predictive Value of the Age‐Adjusted Charlson Comorbidity Index for Outcomes After Hepatic Resection of Hepatocellular CarcinomaWorld Journal of Surgery, 2020
- Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resectionCancer Medicine, 2019
- Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablationEuropean Journal of Radiology, 2012
- Stereotaxy: Breaking the limits of current radiofrequency ablation techniquesEuropean Journal of Radiology, 2010
- Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancerCancer, 2008
- Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis?Journal of Gastroenterology, 2000
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987